New hope for rare nerve disease: rituximab trial targets good responders

NCT ID NCT05136976

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether the drug rituximab can improve disability in people with anti-MAG neuropathy, a rare nerve condition that causes progressive weakness and numbness. The study will enroll 90 participants who have had the disease for 5 years or less and have shown recent worsening. Participants receive two infusions of rituximab or a placebo, and researchers measure changes in daily function after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rituximab (Mabthera) infusion
What this could lead to
If it works, this could provide an effective treatment for anti-MAG neuropathy, a rare nerve disease with no proven therapy.
What could go wrong
Two previous trials of rituximab for this condition failed to show benefit. This trial selects patients with specific characteristics that may improve chances, but success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI MAG NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP - Kremlin-Bicêtre

    RECRUITING

    Paris, 94270, France

    Contact

  • APHP Pitié Salpêtrière

    RECRUITING

    Paris, 75651, France

    Contact

  • CHU Brest - La cavale blanche

    RECRUITING

    Brest, 29200, France

    Contact

  • CHU Grenoble - La tronche

    RECRUITING

    Grenoble, 38700, France

    Contact

  • CHU La Timone - APHM

    RECRUITING

    Marseille, 13915, France

    Contact

  • CHU Lille - Roger Salengro

    RECRUITING

    Lille, 59037, France

    Contact

  • CHU Limoges - Dupuytren

    RECRUITING

    Limoges, 87170, France

    Contact

  • CHU Nancy- Hôpital central

    RECRUITING

    Nancy, 54035, France

    Contact

  • CHU Nice - Pasteur

    RECRUITING

    Nice, 06031, France

    Contact

  • CHU Strasbourg - Hautepierre

    RECRUITING

    Strasbourg, 67091, France

    Contact

  • CHU Toulouse - Pierre-Paul Riquet

    RECRUITING

    Toulouse, 31059, France

    Contact

  • CHU Tours - Bretonneau

    RECRUITING

    Tours, 37044, France

    Contact

  • CHU de Saint-Etienne

    RECRUITING

    Saint-Etienne, France

    Contact

  • HCL lyon

    RECRUITING

    Lyon, 69002, France

    Contact

  • Hôtel-Dieu et Hôpital GR Laënnec - CHU Nantes

    RECRUITING

    Nantes, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.